This activity was originally presented as a part of Directions in Pharmacy 2025.
Program Description
Respiratory syncytial virus (RSV) is a significant yet often underrecognized cause of severe respiratory illness in adults, particularly in older populations and those with comorbid conditions. This program will explore the epidemiology, pathophysiology, and clinical burden of RSV in adults, emphasizing the challenges in diagnosis and differentiation from other respiratory infections. The latest Advisory Committee on Immunization Practices (ACIP) guidelines, the efficacy and safety of available RSV vaccines, and best practices for vaccine implementation based on patient risk factors will be reviewed. The discussion will also highlight best practices for pharmacists to lead patient education efforts, vaccine advocacy, and addressing hesitancy to improve vaccine uptake.
Target audience: Community, ambulatory care, and health system pharmacists
Type of activity: Application
Release date: June 16, 2025
Expiration date: June 16, 2026
Time to complete activity: 1.0 hour
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore risk factors for severe respiratory syncytial virus (RSV) complications in adults and the clinical and economic burden of disease
- Explain the latest ACIP and CDC recommendations and recent efficacy and safety data on RSV vaccination in adults
- Examine strategies to enhance awareness and uptake of RSV vaccination among high-risk adults to improve patient outcomes
Rupal Mansukhani, PharmD, FAPhA, NCNTT
Clinical Professor
Ernest Mario School of Pharmacy
Rutgers University
Piscataway, New Jersey
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-25-199-H06-P. The activity is available for CE credit through June 16, 2026.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Rupal Mansukhani, PharmD, FAPhA, NCNTT
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms